

Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

ANTIGENICS INC /DE/  
Form 8-K  
December 06, 2005

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

December 6, 2005  
Date of Report (Date of earliest event reported)

ANTIGENICS INC

-----  
(Exact name of registrant as specified in its charter)

DELAWARE	000-29089	06-1562417
----- (State or other jurisdiction of incorporation)	----- (Commission File Number)	----- (IRS Employer Identification No.)
630 Fifth Avenue, Suite 2100 New York, NY 10111		10111
----- (Address of principal executive offices)		----- (Zip Code)

212-994-8200  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.05 Costs Associated with Exit or Disposal Activities

On December 6, 2005, Antigenics Inc. issued a press release, attached hereto as Exhibit 99.1, announcing an update to its business strategies and an outline of the timeline for the analysis of its Phase 3 Kidney cancer trial. The content of that press release is incorporated herein by reference.

## Edgar Filing: ANTIGENICS INC /DE/ - Form 8-K

As part of these strategies, the Company has terminated approximately 70 employees and has estimated its costs related to these terminations and other related activities to be approximately \$2 million including severance and other cash costs.

### Item 9.01 Financial Statements and Exhibits

#### (c) Exhibits

99.1 Press Release dated December 6, 2005

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANTIGENICS INC.

Date: December 6, 2005

By: /s/ Garo H. Armen

-----  
Garo H. Armen, Ph.D.  
Chairman and Chief Executive Officer

### EXHIBIT INDEX

Exhibit No.	Description of Exhibit
-----	-----
99.1	Press Release dated December 6, 2005